This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Batista, L. F.Z. Articles by Kaina, B. Search for Related Content PubMed PubMed Citation Articles by Batista, L. F.Z. Articles by Kaina, B.

Differential Sensitivity of Malignant Glioma Cells to Methylating and Chloroethylating Anticancer Drugs: p53 Determines the Switch by Regulating xpc, ddb2, and DNA Double-Strand Breaks

¹ Department of Toxicology, University of Mainz, Mainz, Germany and ² Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil

Requests for reprints: Bernd Kaina, Department of Toxicology, University of Mainz, Obere Zahlbacher Strasse 67, D-55131 Mainz, Germany. Phone: 49-6131-393-3246; Fax: 49-6131-230506; E-mail: kaina{at}uni-mainz.de.

Glioblastoma multiforme is the most severe form of brain cancer. First line therapy includes the methylating agent temozolomide and/or the chloroethylating nitrosoureas [1-(2-chloroethyl)-1-nitrosourea; CNU] nimustine [1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea; ACNU], carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea; BCNU], or lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; CCNU]. The mechanism of cell death after CNU treatment is largely unknown. Here we show that ACNU and BCNU induce apoptosis in U87MG [p53 wild-type (p53wt)] and U138MG [p53 mutant (p53mt)] glioma cells. However, contrary to what we observed previously for temozolomide, chloroethylating drugs are more toxic for p53-mutated glioma cells and induce both apoptosis and necrosis. Inactivation of p53 by pifithrin- or siRNA down-regulation sensitized p53wt but not p53mt glioma cells to ACNU and BCNU. ACNU and BCNU provoke the formation of DNA double-strand breaks (DSB) in glioma cells that precede the onset of apoptosis and necrosis. Although these DSBs are repaired in p53wt cells, they accumulate in p53mt cells. Therefore, functional p53 seems to stimulate the repair of CNU-induced cross-links and/or DSBs generated from CNU-induced lesions. Expression analysis revealed an up-regulation of xpc and ddb2 mRNA in response to ACNU in U87MG but not U138MG cells, indicating p53 regulates a pathway that involves these DNA repair proteins. ACNU-induced apoptosis in p53wt glioma cells is executed via both the extrinsic and intrinsic apoptotic pathway, whereas in p53mt glioma cells, the mitochondrial pathway becomes activated. The data suggest that p53 has opposing effects in gliomas treated with methylating or chloroethylating agents and, therefore, the p53 status should be taken into account when deciding which therapeutic drug to use. [Cancer Res 2007;67(24):11886–95]

This article has been cited by other articles:

				Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system Mol. Cancer Ther., November 1, 2009; 8(11): 3140 - 3150.

				G. Frosina DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy Mol. Cancer Res., July 1, 2009; 7(7): 989 - 999. [Abstract] [Full Text] [PDF]

				L. F.Z. Batista, W. P. Roos, B. Kaina, and C. F.M. Menck p53 Mutant Human Glioma Cells Are Sensitive to UV-C-Induced Apoptosis Due to Impaired Cyclobutane Pyrimidine Dimer Removal Mol. Cancer Res., February 1, 2009; 7(2): 237 - 246. [Abstract] [Full Text] [PDF]

				E. B. Dinca, K. V. Lu, J. N. Sarkaria, R. O. Pieper, M. D. Prados, D. A. Haas-Kogan, S. R. VandenBerg, M. S. Berger, and C. D. James p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts Cancer Res., December 15, 2008; 68(24): 10034 - 10039. [Abstract] [Full Text] [PDF]

				W. Yan, G. Liu, A. Scoumanne, and X. Chen Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function Mutations Cancer Res., August 15, 2008; 68(16): 6789 - 6796. [Abstract] [Full Text] [PDF]

				P. Monfared, A. Winkeler, M. Klein, H. Li, A. Klose, M. Hoesel, Y. Waerzeggers, S. Korsching, and A. H. Jacobs Noninvasive Assessment of E2F-1-Mediated Transcriptional Regulation In vivo Cancer Res., July 15, 2008; 68(14): 5932 - 5940. [Abstract] [Full Text] [PDF]